The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price decrease of -51.50%. However, over the past six months, we’ve seen a stronger performance of -69.39%. The price of BCTX fallen by 5.93% over the last 30 days. And in the last five days, it has fallen by -0.24%.
BriaCell Therapeutics Corp saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $36.60 on 05/09/24, while the lowest price for the same duration was marked at $3.00 on 03/04/25.
52-week price history of BCTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. BriaCell Therapeutics Corp’s current trading price is -88.77% away from its 52-week high, while its distance from the 52-week low is 37.00%. The stock’s price range during this period has varied between$3.00 and $36.60. The BriaCell Therapeutics Corp’s shares, which operate in the Healthcare, saw a trading volume of around 18.14 million for the day, a figure considerably higher than their average daily volume of 0.35 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
BriaCell Therapeutics Corp (BCTX) has experienced a quarterly decline of -31.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 15.25M and boasts a workforce of 18 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.58, with a change in price of -4.47. Similarly, BriaCell Therapeutics Corp recorded 445,115 in trading volume during the last 100 days, posting a change of -52.09%.
BCTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BCTX stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
BCTX Stock Stochastic Average
As of today, BriaCell Therapeutics Corp’s raw stochastic average for the last 50 days stands at 45.97%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 37.10%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 35.71% and 46.01%, respectively.
